David A. Clump, MD, PhD
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, David A. Clump, MD, PhD sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
David A. Clump, MD, PhD: 5 sponsored US clinical trials, none currently recruiting.
David A. Clump, MD, PhD sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adenocarcinoma of the Pancreas, with 1 trials.
Upper-quartile sponsor footprint
David A. Clump, MD, PhD sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Low-Level Laser Therapy for Prevention of Oral Mucositis
NCT02682992
Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
NCT02516969
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
NCT01357525
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
NCT01360593
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT01104922
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
How the David A. Clump, MD, PhD early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Adenocarcinoma of the Pancreas (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
David A. Clump, MD, PhD: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
David A. Clump, MD, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this David A. Clump, MD, PhD page
5 registered trials is a research-attention snapshot, not an endorsement of David A. Clump, MD, PhD or any single study.
- None of David A. Clump, MD, PhD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Adenocarcinoma of the Pancreas is the condition David A. Clump, MD, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adenocarcinoma of the Pancreas trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
David A. Clump, MD, PhD pipeline card: 5 registered trials from official public datasets.Report a data error.